Umeclidinium
Umeclidinium Uses, Dosage, Side Effects, Food Interaction and all others data.
Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). It is available as a once-daily inhalation monotherapy or as a fixed-dose combination product with the long-acting beta2-agonist vilanterol. COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory volume in 1 second (FEV1) of less than 80%. By blocking the M3 muscarinic receptor which is highly expressed in airway smooth muscle of the lungs, umeclidinium inhibits the binding of acetylcholine and thereby opens up the airways by preventing bronchoconstriction. Its use has been shown to provide clinically significant, sustained improvements in lung function.
| Trade Name | Umeclidinium |
| Availability | Prescription only |
| Generic | Umeclidinium |
| Umeclidinium Other Names | Umeclidinium |
| Related Drugs | Trelegy Ellipta, ProAir Digihaler, prednisone, Symbicort, Breo Ellipta, Ventolin, Xopenex, Ventolin HFA, Spiriva, Anoro Ellipta |
| Weight | 62.5mcg(0.0625mg, , 100mcg + 62.5mcg + 25mcg/inh, 200mcg + 62.5mcg + 25mcg/inh |
| Type | Inhalation Powder/inh), Inhalation, Inhalation Powder |
| Formula | C29H34NO2 |
| Weight | Average: 428.595 Monoisotopic: 428.258405759 |
| Protein binding | 89% |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | United States |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Umeclidinium is a long-acting muscarinic antagonist used as a long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
Umeclidinium is also used to associated treatment for these conditions: Chronic Obstructive Pulmonary Disease (COPD)
How Umeclidinium works
Umeclidinium is a long-acting, antimuscarinic agent, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through the inhibition of M3 receptor at the smooth muscle leading to bronchodilation.
Toxicity
In clinical trials, the most common adverse effects of umeclidinium were nasopharyngitis, upper respiratory tract infection, cough, and arthralgia. Atrial fibrillation occurred in <1% of patients, but was more common among patients treated with umeclidinium than in those treated with placebo. Anticholinergics like umeclidinium should be used with caution in patients with narrow-angle glaucoma and in those with prostatic hyperplasia or bladder-neck obstruction. Inhaled medications can cause paradoxical bronchospasm, which can be fatal.
Food Interaction
No interactions found.Umeclidinium Drug Interaction
Moderate: albuterol / ipratropiumUnknown: fluticasone / salmeterol, umeclidinium / vilanterol, fluticasone / vilanterol, sulfamethoxazole / trimethoprim, ubiquinone, copper gluconate, formoterol / mometasone, omega-3 polyunsaturated fatty acids, glycerin, metoprolol, metoprolol, albuterol, bioflavonoids, beclomethasone, budesonide / formoterol, fluticasone / umeclidinium / vilanterol, acetaminophen, albuterol, cholecalciferol
Umeclidinium Disease Interaction
Major: milk protein allergiesModerate: anticholinergic effects, severe liver impairment
Volume of Distribution
Mean volume of distribution was 86 L.
Elimination Route
Cmax occurred at 5 to 15 minutes, with steady state concentrations arriving in 14 days with 1.8-fold accumulation.
Half Life
The effective half-life after once daily dosing is 11 hours.
Elimination Route
Following intravenous dosing with radiolabeled umeclidinium, mass balance showed 58% of the radiolabel in the feces and 22% in the urine.
Innovators Monograph
You find simplified version here Umeclidinium
